Bioventus LLC has filed plans to go public on the Nasdaq stock exchange, a move that could net the company $100 million. The company filed the plans on January 20, 2021, and if it is successful, it would trade under the ticker "BVS" on the Nasdaq. This is the second time the company has filed to go public. In 2016, the company said it was exploring a $150 million initial public offering, but rescinded the application, citing bad market conditions. Thomas Hill, a spokesman for the company, declined to comment on the initial public offering, citing a company quiet period.